Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform.
Excellent balance sheet with limited growth.
Share Price & News
How has Wave Life Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: WVE's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: WVE underperformed the US Pharmaceuticals industry which returned 7.8% over the past year.
Return vs Market: WVE underperformed the US Market which returned 9.3% over the past year.
Price Volatility Vs. Market
How volatile is Wave Life Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StHere's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
1 month ago | Simply Wall StImagine Owning Wave Life Sciences (NASDAQ:WVE) While The Price Tanked 69%
2 months ago | Simply Wall StHow Many Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Have Insiders Sold, In The Last Year?
Is Wave Life Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate WVE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate WVE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: WVE is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: WVE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate WVE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: WVE is overvalued based on its PB Ratio (16.6x) compared to the US Pharmaceuticals industry average (3.2x).
How is Wave Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: WVE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: WVE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: WVE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: WVE's revenue (33.8% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: WVE's revenue (33.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: WVE is forecast to be unprofitable in 3 years.
How has Wave Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WVE is currently unprofitable.
Growing Profit Margin: WVE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: WVE is unprofitable, and losses have increased over the past 5 years at a rate of -44% per year.
Accelerating Growth: Unable to compare WVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.5%).
Return on Equity
High ROE: WVE has a negative Return on Equity (-685.41%), as it is currently unprofitable.
How is Wave Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: WVE's short term assets ($149.8M) exceed its short term liabilities ($118.9M).
Long Term Liabilities: WVE's short term assets ($149.8M) exceed its long term liabilities ($91.0M).
Debt to Equity History and Analysis
Debt Level: WVE is debt free.
Reducing Debt: WVE has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: WVE has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: WVE has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 46.6% each year.
What is Wave Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WVE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WVE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of WVE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Bolno (45yo)
Dr. Paul B. Bolno, M.D., MBA has been the Chief Executive Officer and President of WAVE Life Sciences Ltd. since December 2013. Prior to joining WAVE, Dr. Bolno served at GlaxoSmithKline from 2009 to 2013 ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD3.58M) is above average for companies of similar size in the US market ($USD2.22M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
|Senior Vice President of Drug Discovery||5.83yrs||US$1.24m||0.042% $145.9k|
|Chief Medical Officer||1.5yrs||US$1.27m||0.051% $176.1k|
|Interim Chief Financial Officer||0.42yr||no data||0.0061% $21.4k|
|Senior Vice President of Finance & Operations||3.33yrs||no data||no data|
|Head of Investor Relations||1.17yrs||no data||no data|
|General Counsel||4.08yrs||no data||no data|
|Senior VP of Corporate Development & Head of Emerging Areas||3.42yrs||US$1.68m||0.035% $120.7k|
|Senior Vice President of Corporate Affairs & Patient Advocacy||0.42yr||no data||no data|
|Senior Vice President of Therapeutics Discovery||0.083yr||no data||no data|
Experienced Management: WVE's management team is considered experienced (2.4 years average tenure).
|Independent Director||0.75yr||US$259.09k||no data|
|Independent Chairperson||2.67yrs||US$206.11k||no data|
|Independent Director||7.67yrs||US$150.88k||no data|
|Independent Director||3.33yrs||US$150.88k||no data|
|Independent Director||5.42yrs||US$151.60k||no data|
|Independent Director||7.92yrs||US$151.33k||no data|
|Independent Director||0.75yr||US$258.28k||no data|
|Independent Director||0.75yr||US$258.55k||no data|
Experienced Board: WVE's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Wave Life Sciences Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Wave Life Sciences Ltd.
- Ticker: WVE
- Exchange: NasdaqGM
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$348.577m
- Shares outstanding: 34.89m
- Website: https://www.wavelifesciences.com
Number of Employees
- Wave Life Sciences Ltd.
- Marina One East Tower
- No. 12-00, 7 Straits View
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|WVE||NasdaqGM (Nasdaq Global Market)||Yes||Ordinary Shares||US||USD||Nov 2015|
|1U5||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Nov 2015|
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/02 04:52|
|End of Day Share Price||2020/06/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.